Antileukemia Activity and Mechanism of Platinum(II)-Based Metal Complexes

Molecules. 2022 Dec 17;27(24):9000. doi: 10.3390/molecules27249000.

Abstract

Transition metal complexes have continued to constitute an appealing class of medicinal compounds since the exceptional discovery of cisplatin in the late 1960s. Pt(II)-based complexes are endowed with a broad range of biological properties, which are mainly exerted by targeting DNA. In this study, we report a significant biological investigation into and computation analyses of four Pt(II)-complexes, namely, LDP-1-4, synthesized and characterized according to previously reported procedures. Molecular-modelling studies highlighted that the top two LDP compounds (i.e., LDP-1 and LDP-4) might bind to both matched and mismatched base pair sites of the oligonucleotide 5'-(dCGGAAATTACCG)2-3', supporting their anticancer potential. These two complexes displayed noteworthy cytotoxicity in vitro (sub-micromolar-micromolar range) against two leukaemia cell lines, i.e., CCRF-CEM and its multi-drug-resistant counterpart CEM/ADR5000, and remarkable anti-angiogenic properties (in the sub-micromolar range) evaluated in an in vivo model, i.e., a chick embryo chorioallantoic membrane (CAM) assay.

Keywords: CAM assay; anticancer agents; leukemia cell lines; molecular modeling studies; platinum(II)-based complexes.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Chick Embryo
  • Cisplatin
  • Coordination Complexes* / pharmacology
  • DNA
  • Platinum / pharmacology

Substances

  • Platinum
  • Antineoplastic Agents
  • Coordination Complexes
  • Cisplatin
  • DNA

Grants and funding

This research received no external funding. It was partially aided by the internal grant FFABR_PA_MICALE_ATENEO_2020_II_EDIZIONE.